Articles
Every piece is research-cited and updated as the science changes. Filter by topic and life stage — or browse the full archive below.
Results
Comprehensive symptom map, grouped by body system, with research citations on each.
KNDy neurons, the thermoneutral zone, and what fezolinetant changes about treatment options.
Estradiol, cortisol, GABA, and the evidence on CBT-I, MHT, and the supplements women try first.
What changes, what doesn't, and which interventions actually have RCT evidence in midlife women.
Why 50–70% of postmenopausal women have GSM and most cases go untreated. The evidence on vaginal estrogen, DHEA, lasers, and lubricants.
The 2002 WHI study, the 2022 NAMS update, and where the field stands now.
CJC-1295, BPC-157, Tesamorelin, PT-141. Where the evidence is real, where it isn't.
SWAN bone substudy data, the LIFTMOR resistance training trial, and how bisphosphonates compare to denosumab and romosozumab.
Black cohosh, red clover, soy, maca, vitamin D, magnesium, omega-3, ashwagandha, DIM. Each graded against the literature.
Try removing one — or browse the full archive.
Evidence-rated picks
We list products with published clinical evidence and verifiable quality signals (NSF / NAMS / FDA / CLIA). Some links are affiliate — that never changes what we include. How we choose.
Bonafide
In a 12-week clinical trial, hyaluronic acid suppositories improved vaginal dryness comparably to vaginal estrogen — with 84% of participants reporting symptom relief.
Read the trial (PMC9408661) → Owned by Pharmavite (NSF-certified parent)Thorne
A 2024 meta-analysis of randomized trials found magnesium supplementation modestly improved sleep quality and reduced sleep onset latency in adults with insomnia symptoms.
Read the meta-analysis (PMC11136869) → NSF-certified facility · Third-party testedLetsGetChecked
Vitamin D insufficiency is widespread in postmenopausal women and is associated with accelerated bone loss. Testing 25(OH)D before supplementing helps target the right dose, per NIH guidance.
Read the NIH fact sheet → CLIA-accredited labs · Physician-reviewed resultsWinona
The 2022 NAMS Hormone Therapy Position Statement concludes hormone therapy remains the most effective treatment for vasomotor symptoms and GSM, with favorable risk profile for healthy women under 60 or within 10 years of menopause onset.
Read the NAMS 2022 statement → FDA-approved estradiol · Licensed cliniciansResearch resource
If you're evaluating peptide protocols for menopause, supplier quality is the variable women most often overlook. PeptidesRated lists 50+ providers that prove batch purity — with Certificates of Analysis, independent lab testing, and pricing compared side by side.
External resource. We don't sell peptides.